| ¿µ¹® | blood-brain barrier(BBB) | ÇÑ±Û | Ç÷³úÀ庮 |
|---|---|---|---|
| ¼³¸í | ³ú¿Í ô¼ö¿¡´Â Ç÷·ù·ÎºÎÅÍ ¾î¶² ¹°ÁúÀÌ À¯ÀԵǴ °ÍÀ» ¸·´Â À庮ÀÌ´Ù. À̰ÍÀº ³ú¿Í ô¼ö¿¡ Á¸ÀçÇÏ´Â ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºÀÌ ºñ±³Àû ´Ù¸¥ ¸ð¼¼Ç÷°üÀÇ Åõ°ú¼ºº¸´Ù ¶³¾îÁö±â ¶§¹®ÀÌ´Ù. |
||
| ¿µ¹® | blood sugar | ÇÑ±Û | Ç÷´ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾× ¼Ó¿¡ Æ÷ÇԵǾî ÀÖ´Â Æ÷µµ´ç. ³ú¿Í ÀûÇ÷±¸ÀÇ ¿¡³ÊÁö¿øÀÌ µÇ°í, ±× ¾çÀº ¿îµ¿, ½Ä»ç µûÀ§¿¡ ÀÇÇÏ¿© ´Þ¶óÁø´Ù. °Ç°ÀÎÀÇ ¾ÆÄ§ °øº¹½Ã Ç÷Áß Æ÷µµ´ç ³óµµ´Â 60~100mg/dL ÀÌÁö¸¸ ±âŸÀÇ ´çÁú Áï °ú´ç, °¥¶ôÅ佺, 5ź´çÀº ¹Ì·®À̸ç ÀϹÝÀûÀ¸·Î Ç÷´çÀ̶ó Çϸé Ç÷Á߯÷µµ´çÀ» ÀǹÌÇÑ´Ù. Ç÷´çÀº »ýüÀÇ ¿¡³ÊÁö¿øÀ¸·Î¼ °¡Àå Áß¿äÇÑ ¹°ÁúÀÌ´Ù. ±× ³óµµ´Â Àå°üÀ¸·ÎºÎÅÍÀÇ Èí¼ö, °£¿¡ ÀÖ¾î¼ÀÇ ´ç½Å»ý°ú ±Û¸®ÄÚ°ÕÀÌ ÇÕ¼º-ºÐÇØ, ¸»ÃÊÁ¶Á÷ÀÇ ´çÀÌ¿ë ÄáÆÏÀ¸·ÎºÎÅÍÀÇ ¹è¼³ µî ¿©·¯ ÀÎÀÚ¿¡ ÀÇÇØ Á¿ìµÇ¸ç ±× Á¶Àý¿¡´Â ÀÚÀ²½Å°æ°ú °¢Á¾ È£¸£¸óÀÌ ¹ÐÁ¢ÇÏ°Ô °ü°èÇÑ´Ù. ƯÈ÷ Ç÷´çÀúÇÏÀÛ¿ë¿¡´Â Àν¶¸°ÀÌ, ±×¸®°í Ç÷´ç»ó½ÂÀÛ¿ë¿¡´Â ¿¡Çdz×ÇÁ¸°, ±Û·çÄ«°ï, ¼ºÀåÈ£¸£¸ó, ºÎ½Å°ÑÁúÈ£¸£¸ó, ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, °©»ó»ù È£¸£¸óÀÌ °ü°è°¡ ÀÖÀ¸¸ç ±×°ÍµéÀÇ ´ëÇ× ¹× ÇùÁ¶ÀÛ¿ë¿¡ ÀÇÇØ Ç÷´çÄ¡°¡ Á¶ÀýµÈ´Ù. |
||
| ¿µ¹® | blood pressure | ÇÑ±Û | Ç÷¾Ð |
|---|---|---|---|
| ¼³¸í | Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÏ´Â °ÍÀ¸·Î ´ë°³ Ưº°ÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð(systolic blood pressure)°ú À̿ϱâÇ÷¾Ð(diastolic blood pressure)ÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí, À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ ¿¹¸¦ µé¾î 120/80mmHgÀ̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù. |
||
| ¿µ¹® | blood | ÇÑ±Û | Ç÷¾×, ÇÇ |
|---|---|---|---|
| ¼³¸í | ¼øÈ¯±â, Áï ½ÉÀå°ú Ç÷°ü ¾ÈÀ» ¼øÈ¯ÇÏ´Â À¯µ¿¼ºÀÇ Á¶Á÷À» ¸»ÇÑ´Ù. Ç÷¾×Àº Àüü üÁßÀÇ ¾à 8%¸¦ Â÷ÁöÇϸç, ºñÁßÀº 1,056~1,059, Á¡µµ´Â ¾à 4.5, pH´Â 7.4ÀÌ´Ù. Ç÷¾×Àº ¾×ü¼ººÐÀÎ Ç÷Àå°ú °Å±â¿¡ ¶°µ¹°í ÀÖ´Â ¼¼Æ÷¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷ÀåÀº Àüü Ç÷¾×ÀÇ 55%¸¦ Â÷ÁöÇÏ¸ç ¼öºÐ, ´Ü¹éÁú, Ç÷´ç, Áö¹æÁú, ¹«±â¿°·ù, Áú¼ÒÈÇÕ¹°·Î ÀÌ·ç¾îÁø´Ù. ¼¼Æ÷¼ººÐÀº Àüü Ç÷¾×ÀÇ 45%¸¦ Â÷ÁöÇϸç ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. Ç÷¾×ÀÇ ÁÖ¿ä ±â´ÉÀº Àü½Å Á¶Á÷À¸·Î »ê¼Ò¿Í ¿µ¾çºÐ °°Àº ÇÊ¿äÇÑ ¹°ÁúÀ» ¿î¹ÝÇÏ¸ç ºÒÇÊ¿äÇÑ ¹°ÁúÀ» ¹è¼³±â°üÀ¸·Î ¿î¹ÝÇÏ´Â ÀÏÀÌ´Ù. ±× ¹Û¿¡ »ýü¿¡ ÇØ·Î¿î ¹°ÁúÀ̳ª ¼¼±ÕÀ» Á¦°ÅÇϰí, ³»ºÎȯ°æÀÇ Çâ»ó¼ºÀ» À¯ÁöÇϸç, ü¿ÂÀ¯Áö¿Í »ýü ¹æ¾î ±â´ÉÀ» ÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº ¿©·¯ °¡Áö ¼¼Æ÷ Ç÷±¸¿Í ±× ¼¼Æ÷¸¦ Æ÷ÇÔÇÏ´Â ¸¼Àº ¾×üÀÎ Ç÷Àå·Î ±¸¼ºµÇ¾î ÀÖ´Ù. Ç÷±¸´Â ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ÀûÇ÷±¸´Â ºÓÀº »öÀ» ¶ì´Â ¼¼Æ÷·Î »ê¼Ò¸¦ ¸öÀÇ Á¶Á÷À¸·Î ¿î¹ÝÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. Ç÷¼ÒÆÇÀº Ç÷¾×ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷ÀÌ´Ù. ¹éÇ÷±¸´Â Àΰ£ÀÇ ¸é¿ª¿¡ °ü°èÇÏ´Â ¼¼Æ÷ÀÌ¸ç ±¸Ã¼ÀûÀ¸·Î ´ÙÀ½°ú °°Àº ¼¼Æ÷µéÀÌ ÀÖ´Ù. 1.°ú¸³±¸(granulocyte): °ú¸³±¸¶õ ¹éÇ÷±¸ÀÇ 60%¸¦ Â÷ÁöÇϸç, ¼¼Æ÷¼Ó¿¡ ƯÀÌÇÑ °ú¸³À» °¡Áö°í ÀÖ´Â ¼¼Æ÷À̸ç, ´ÙÀ½°ú °°Àº 3°¡ÁöÀÇ ¼¼Æ÷°¡ À̰÷¿¡ Æ÷ÇÔÀÌ µÈ´Ù. -È£¿°±â±¸(basophil): ¿°±â¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ´Ù. ºÒ±ÔÄ¢ÇÑ ¸ð¾çÀÇ ¼¼Æ÷·Î Ǫ¸¥ »öÀ» ¶ì´Â °ú¸³ÀÌ ³Ê¹« ¸¹ÀÌ ÀÖ¾î¼ ÇÙÀÌ Àß º¸ÀÌÁö ¾Ê´Â´Ù. -È£»ê±¸(eosinophil): »ê¼º¿°»ö¾à¿¡ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö°í ÀÖ°í, ´ë°³ ±â»ýÃæÀÇ °¨¿°À̳ª, ¾Ë·¯Áö¿¡¼ ¸¹ÀÌ Áõ°¡ÇÑ´Ù. ´ë°³ 2°³ÀÇ ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº °ÍÀ¸·Î À̾îÁ® ÀÖ´Ù. -È£Áß±¸(neutrophil): »ê¼º¿°»ö¾àÀ̳ª ¿°±â¼º¿°»ö¾à¿¡ ÀÇÇÏ¿© ¸ðµÎ Àß ¿°»öµÇ´Â °ú¸³À» °¡Áö´Â ¼¼Æ÷·Î ´ë°³ 3°³ÀÇ ÇÙÀ» °¡Áø´Ù. ±×¸®°í ÇÙ»çÀÌ¿¡ °¡´Â ½Ç°°Àº ±¸Á¶¹°ÀÌ ÀÖ¾î¼ ÇÙÀ» ¼·Î À̾îÁÖ°í ÀÖ´Ù. 2.´ÜÇÙ±¸(monocyte): ´Ù°¢Çü¸ð¾çÀ» °¡Áø ¼¼Æ÷·Î °ú¸³À» °¡Áö°í ÀÖÁö ¾Ê´Ù. ¿Ü°è·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» Àâ¾Æ¸Ô´Â ¿ªÇÒ°ú ±×°Í¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÏ´Â ¿ªÇÒÀ» ÇÏ¿© ¸é¿ª¿¡ °ü°èÇÑ´Ù. À̰ÍÀÌ Ç÷¾× Áß¿¡ Á¸ÀçÇÏÁö ¾Ê°í Á¶Á÷¿¡ °íÁ¤µÇ¾î ÀÖ´Â °æ¿ì¿¡ À̰ÍÀ» Å«Æ÷½Ä¼¼Æ÷¶ó°í ÇÑ´Ù. 3.¸²ÇÁ±¸(lymphocyte): ÀÛÀº ¿øÇüÀÇ ¼¼Æ÷·Î ¸é¿ª¿¡ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù. |
||
| TT | tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te... |
|---|---|
| WBAPTT | whole blood activated partial thromboplastin time |
| WBCT | whole-blood clotting time |
| WBPTT | whole-blood partial thromboplastin time |
| WBRT | whole-blood recalcification time |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |
|---|---|
| activated clotting time | The most common test used for coagulation time in cardiovascular surgery. (05 Mar 2000) |
| activated partial thromboplastin time | The time needed for plasma to form a fibrin clot following the addition of calcium and a phospholipid reagent; used to evaluate the intrinsic clotting system. (05 Mar 2000) |
| A-H conduction time | Forward conduction of the cardiac impulse from atria to ventricles via the A-V node or any bypass tract, represented in the electrocardiogram by the P-R interval. P-H conduction time is from the onset of the P wave to the first high frequency component of the His bundle electrogram (normally 119 ± 38 msec); A-H conduction time is from the onset of the first high frequency component of the atrial electrogram to the first high frequency component of the His bundle electrogram (normally 92 ± 38 msec); P-A conduction time is from the onset of the P wave to the onset of the atrial electrogram (normally 27 ± 18 msec). (05 Mar 2000) |
| association time | Time elasping between a stimulus and the verbalised response to it. (05 Mar 2000) |
| biologic time | The concept that our appreciation of time varies with age and is governed by the neural organization of the individual; it obeys a logarithmic rather than an arithmetic law. (05 Mar 2000) |
| bleeding time | <haematology> A test which measures the time it takes for small blood vessels to close off and bleeding to stop. Abnormal results can be seen in those with congenital or acquired platelet function disorders or thrombocytopenia. (27 Sep 1997) |
| P-A conduction time | See: atrioventricular conduction. (05 Mar 2000) |
| generation time | <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle. (18 Nov 1997) |
| reaction time | The time from the onset of a stimulus until the organism responds. (12 Dec 1998) |
| real-time ultrasonography | Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion. (05 Mar 2000) |
| recognition time | The interval between the application of a stimulus and the recognition of its nature. (05 Mar 2000) |
| partial thromboplastin time | Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy. (12 Dec 1998) |
| relaxation time | Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value. (18 Nov 1997) |
| median time to elimination | <pharmacology> The time it takes one half of a drug to be eliminated from the body. (09 Oct 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|